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Abstract 
AIM: The study aimed to investigate the effect of drug-related problems (DRPs) on changes in blood glucose level 
(BGL) in the treatment of type 2 diabetes mellitus (T2DM) patients. 
METHODS: This three-month prospective cross-sectional study was conducted to patients of T2DM with 
complications hospitalised in Haji Adam Malik (HAM) Hospital, Medan, Indonesia period from July to October 
2018. DRPs were identified and classified by using Cipolle DRP classification and trustable literature. The data 
obtained were analysed by Chi-Square test (p < 0.05 implied that there was a significant relationship). 
RESULTS: This study involved 81 T2DM patients, 52 (64.2%) of the patients were male, and 29 (35.8%) of them 
were female. Most (30.9%) of patients were at the age of 51-60 years. Combination of rapid-acting and long-
acting insulin was the most frequently provided antidiabetic drugs (69.1%). There were 68 DRPs experienced by 
32 (39.5%) of the patients. Percentage of DRP experienced by the 32 patients by number: 1 DRP, 53.1; 2 DRPs, 
28.1; 3 DRPs, 3.1; 4 DRPs, 3.1; 5 DRPs, 3.1; 7 DRPs, 9.3. This study showed that 27.2% and 12.3 % of the 
patients had hyperglycemia and hypoglycemia, respectively. There was no significant relationship between BGL 
and indication without drug therapy (p = 0.064), ineffective provided drug (p = 0.079), and there was a significant 
relationship between BGL and irrational dose (p = 0.000). Furthermore, there was a significant relationship 
between hypoglycemia and adverse drug reaction (p = 0.000). 
CONCLUSION: DRPs are common among T2DM patients and still required the attention and appropriate actions 
of healthcare providers. 
 
 
 
 
 
Introduction 
 
Diabetes mellitus (DM) is a metabolic disease 
characterised by high BGLs in the body caused by 
defects in insulin secretion, insulin action, or both. In 
2017, Indonesia was ranked as the 6th highest 
prevalence of diabetes in the world in which the 
number of people with diabetes mellitus reached 10.3 
million and is expected to rise to 16.7 million in 2045 
[1]. It was estimated 1 death every 6 to 10 seconds 
caused by its complications around the world [2]. 
Hyperglycemia that occurs, over time, can damage 
various body organs, especially the nerves and blood 
vessels. Macrovascular and microvascular 
complications can occur in patients with diabetes 
mellitus. Common developed macrovascular 
complications that occur in people with diabetes is 
coronary heart disease, blood vessel disease in the 
brain, and peripheral vascular disease [3]. 
The disease and its complications 
experienced by diabetes mellitus patients required 
polypharmacy (multiple drug therapy) which in turn 
can cause DRPs [4], that actually or potentially 
interfere with the desired outcome of therapy [5]. This 
condition can further worsen the patients’ quality of 
life, increase their length of stay and treatment costs. 
On the other side, the limitation of health resources is 
a serious problem in the universal health coverage 
era. Facts indicated that the National Health 
Insurance has been facing financial difficulties to run 
the program [6], [7]. These problems should be 
responded and resolved.  
Several studies on DRPs have been 
conducted by researchers applying different 
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classification methods. In 2018, a study performed in 
Tegal, Indonesia stated that drug dose and drug 
choice problems were the highest DRPs of the overall 
incidences [8]. Also, another study conducted in 
Medan proved that the most frequently occurred DRP 
was indication without therapy and there was no 
significant association between the patients’ education 
and DRPs (p = 0.88) [9]. Research on DRPs is still 
limited in Indonesia. 
The study aimed to investigate the effect of 
DRPs on changes of BGLs in the treatment of T2DM 
patients. This study focused on antidiabetic utilisation, 
identification and analysis of DRPs in the 
management of T2DM as well as the association 
between DRPs and changes of BGLs. 
 
 
Methods 
 
This prospective cross-sectional study was 
undertaken on T2DM inpatients admitted to HAM, 
Medan, Indonesia. In this study, the number of 
patients recruited as subjects was 81 hospitalised 
from July to October 2018. The patients diagnosed 
with T2DM with a complication, aged ≥ 18 years, 
received oral antidiabetics or insulin and other 
medicines (combination therapy) and have provided 
their consent were included in this study. Ethical 
clearance of this study was obtained from The Ethical 
Commission of Health Research, Faculty of Nursing, 
Universitas Sumatera Utara, Medan. Characteristics 
of patients, including gender, age, and co-morbidities, 
were recruited from their medical records. Drugs 
provided to the patients, important laboratory results 
and BGL as clinical outcome were also extracted from 
their medical records. 
Characteristics of T2DM patients and drug 
utilisation were descriptively analysed. Incidence of 
DRPs in the management of T2DM was identified and 
analysed based on Cipolle DRP classification system 
that comprises indication without drug therapy, 
ineffective provided drug, too low doses, too high 
doses, drug interaction and adverse drug reaction 
[10]. The analysis of the occurred DRPs referred to 
trustable literatures including the authority on drug 
interactions, a sourcebook of adverse interactions, 
their mechanisms, Medscape Reference, IBM 
Micromedex Reference [11], [12], [13], [14] and 
guidelines for the management of T2DM [15], [16], 
[17], [18]. The BGLs of the T2DM patients were 
grouped into 3 categories that are normoglycemia (< 
200 mg/dl), hyperglycemia (≥ 200 mg/dl), and 
hypoglycemia (< 70 mg/dl). The relationship between 
the occurred DRPs as an independent variable with 
BGL as a dependent variable was analysed by Chi-
Square tests [19] in the program of Statistical 
Package for the Social Sciences (SPSS) version 25 (p 
< 0.05 is considered significant). 
Results 
 
During the study period, there were 81 
patients fulfilled the inclusion criteria consisted of 
64.2% male and 35.8% female. Table 1 shows the 
demographics of T2DM patients. Most (30.9%) of the 
patients were at the age of 51-60 years. The number 
of drugs given to the patients varies, ranging from 6 to 
20 items. The most common complications or 
comorbidity experienced by the patients were; heart 
failure (11.8%) and hypertension (9.1%).  
Table 1: Demographics of the T2DM patients (n = 81) 
Characteristics % of patients 
Gender: 
Male 
Female  
 
64.2 
35.8 
Age: 
≤ 40 
41-50 
51-60 
61-70 
71-80 
≥ 81 
 
7.4 
25.9 
30.9 
24.7 
8.6 
2.5 
Complications/co-morbidities: 
Heart failure 
Hypertension 
Coronary heart disease 
Ischemic stroke 
Tuberculosis 
Pneumonia 
Others 
 
11.8 
9.1 
7.3 
6.8 
5.5 
5.5 
< 5 
 
 
Drug utilisation and clinical outcomes in the 
treatment of The T2DM patients are listed in Table 2. 
The most widely administered antidiabetic drug was a 
combination of rapid-acting and long-acting insulins 
received by 56 (69.1%) of the patients and insulin 
monotherapy by 18 (22.2%) of the patients. Table 2 
also shows that, based on the results of random 
BGLs, most (60.5%) of the patients achieved good 
glycemic control or normoglycemia. 
Table 2: Drug utilisation and clinical outcome in the treatment 
of T2DM patients (n = 81) 
Drug therapy % of patients provided antidiabetics 
Monotherapy of insulin: 
Insulin aspart 
Insulin aspart/protamine 
Combination insulin: 
Insulin aspart + detemir 
Insulin aspart + glargine 
Insulin glulisine + glargine 
Insulin glulisine + detemir 
Insulin aspart/protamine + glargine 
Insulin + oral antidiabetic drugs: 
Insulin aspart + metformin 
Insulin aspart + metformin + glimepiride 
Insulin aspart + insulin glargine + glimepiride 
Insulin aspart + insulin detemir + metformin 
Oral antidiabetic drug: 
Metformin 
Oral antidiabetic combination: 
Metformin + glimepiride 
Glimepirid + pioglitazone 
 
2.5 
22.2 
 
26 
24.7 
11.1 
6.2 
1.2 
 
1.2 
1.2 
1.2 
1.2 
 
1.2 
1.2 
1.2 
1.2 
Random BGL: 
Normoglycemia (< 200 mg/dl) 
Hyperglycemia (≥ 200 mg/dl) 
Hypoglycemia (< 70 mg/dl) 
 
 
60.5 
27.2 
12.3 
 
The incidence of DRPs in the treatment of 
T2DM patients is shown in Table 3. In this study, there 
were 68 DRPs identified, which affected BGLs. The 
most common DRPs found were drug interactions 
(45.6%) and inadequate dose (32.4%). Adverse drug 
reactions were found in 10 patients who experienced 
hypoglycemia as the effects of insulin or an oral 
Hartuti et al. The Effect of Drug Related Problems on Blood Glucose Level in the Treatment of Patients with Type 2 Diabetes Mellitus 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
antidiabetic sulfonylurea. Furthermore, the present 
study also found indication without drug therapy 
(2.9%) and ineffective provided drug (4.4%).  
Table 3: Incidence of DRPs experienced by the T2DM patients 
DRP category Frequency Percentage 
(%) 
Description 
Indication without 
drug therapy 
2 2.9 Provision of rapid-acting insulin as 
monotherapy 
Ineffective provided 
drug 
3 4.4 Ineffective combination of rapid-acting 
insulin with metformin, ineffective 
combination of premixed insulin with 
long-acting insulin and metformin 
provided to patients with CHF grade III 
Inadequate dose 22 32.4 The dose of insulin was not enough 
Adverse drug 
reaction 
10 14.7 Hypoglycemia 
Drug interaction 31 45.6 The interaction of antidiabetic drugs 
with other drugs that have a 
hypoglycemic effect 
 
 
The results of this study showed that 32 
patients did not achieve the desired BGL in which 
there were 22 patients with hyperglycemia and the 
other 10 patients experienced hypoglycemia. DRPs 
have a significant correlation with changes in BGLs 
experienced by hospitalised patients with T2DM in 
HAM hospital. Relationship between DRPs with 
changes in BGL of the T2DM patients during 
treatment is shown in Table 4. As shown in the Table, 
the BGLs were classified into hyperglycemia, 
hypoglycemia, and normoglycemia. There was no 
significant relationship between indication without 
drug therapy with the hyperglycemic condition of the 
patients (p = 0.064). There was also no significant 
relationship between ineffective provided drug and 
hyperglycemia (p = 0.079). On the other hand, there 
was a significant relationship between inadequate 
dose and hyperglycemia (p = 0.000). Additionally, 
there was a significant relationship between adverse 
drug reaction and hypoglycemia (p = 0.000). 
Table 4: Relationship between DRPs with changes in BGL of 
the T2DM patients (n = 81) 
Primary Domain 
Number of cases by clinical outcome 
p-Value 
Hyperglycemia Hypoglycemia Normoglycemia 
Indication without  
drug therapy: 
 
 
 
 
 
 
 
 
Yes 2 0 0 0.064 
No 20 10 49  
Ineffective provided 
Drug: 
 
 
 
 
 
 
 
 
Yes 3 0 0 0.079 
No 19 10 49  
Inadequate dose:     
Yes 22 0 0 0.000 
No 0 10 49  
Drug interaction      
Yes 46 31 94 0.000 
No 4 0 10  
Adverse Drug  
Reaction  
 
 
 
 
 
 
 
 
Yes 0 10 0 0.000 
No 22 0 49  
 
 
Discussion 
 
The present study showed that T2DM was 
more prevalent in male compared to female. Other 
studies also found similar results [20], [21]. The age 
group of 51-60 years was more prevalent in this study. 
A study conducted in India revealed that the disease 
was more prevalent in the age group of 40-79 years 
[22]. This difference could be associated with the 
differences in social, economic conditions and lifestyle 
[23].  
The most widely provided antidiabetic drug 
was a combination of rapid and long-acting insulins, 
followed by insulin as a monotherapy. This study 
supported the study undertaken in Malaysia, in which 
it was revealed that insulin was the most widely 
prescribed [20]. In contrast, another study revealed 
that metformin was the most commonly prescribed 
drug, followed by glibenclamide [21]. The difference 
was probably due to the different prescribing patterns 
between one hospital and others.  
The American diabetes association 
recommends random blood glucose target of less 
than 200 mg/dL. A patient is categorised as 
hypoglycemia if he or she has BGL less than 70 
mg/dL. Monitoring of BGL is commonly done by 
measuring the random BGLs on the last day of 
hospitalisation. To diagnose whether a patient is 
hypoglycemia, BGL was measured at the beginning of 
the incidence. In this study, 32 patients did not 
achieve the desired BGL consisted of 22 patients with 
hyperglycemia and 10 patients with hypoglycemia.  
There were 68 DRPs experienced by those 
patients. The most frequently DRPs contributed to 
BGL was drug interaction, which had a significant 
relationship with hypoglycemia. Inadequate dose was 
the second most DRPs contributed to the change in 
BGL in which it had a significant relationship with 
hyperglycemia. Neither indication without drug therapy 
nor ineffective provided drug had a significant 
relationship with hyperglycemia. Drug selection 
problems tend to be in small amounts, so they did not 
affect changes in hyperglycemia. Indication without 
drug therapy was experienced by 2 (2.5%) of the 
hyperglycemia patients that received rapid-acting 
insulin as a monotherapy. 
Additionally, inappropriate drug combinations 
consisted of an ineffective combination of rapid-acting 
insulin with metformin and combination of premixed 
insulin with long-acting insulin were received by 2 
(2.5%) of the patients. Based on clinical practice 
guidelines, the first targeting treatment of 
hyperglycemia is to monitor basal BGL in fasting and 
pre-meal conditions. It can be achieved by 
administration of oral antidiabetic or insulin therapy. 
The combination of antidiabetic oral drug and insulin 
is started from the administration of basal insulin. 
Rapid or short-acting insulin is used to 
achieve the target of prandial BGL. In a condition 
where BGLs throughout the day are still uncontrollable 
despite having received basal insulin, it is necessary 
to provide a combination of basal and prandial insulin 
[16], [18]. This present study also proved the 
presence of contra-indication in 1 patient (1.2%) with 
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grade III heart failure in which the patient has 
administrated metformin as oral antidiabetic therapy. 
The previous study on DRP conducted by Zaman Huri 
and Fun Wee [20] found that approximately 24% of 
T2DM patients with hypertension and chronic kidney 
disease received metformin. Provision of metformin is 
a contraindication in this group of patients. This 
difference can be associated with many complicated 
factors, including the difference in prescribing pattern 
and the number of comorbidities suffered by the 
patients. In this study, there was a relatively small 
incidence of drug selection problems, but it is still 
required the attention of physicians when prescribing 
antidiabetic drugs to T2DM patients with 
complications [20]. 
Drug-related problems of inadequate dose 
related to the achievement of target BGLs were 
indicated in 22 patients with hyperglycemia. The result 
was different from the study conducted in Nigeria [21]. 
This difference cannot be explained due to the lack of 
information what drugs were found subtherapeutic 
dosages in the study. Besides, this study assessed 
the effect of DRPs on changes in BGLs as glycemic 
control. There were found an inadequate dose of 
insulin in this study related to the target of BGLs that 
were not reached, hyperglycemia. Clinical practice 
guidelines state that the initial dose of basal insulin 
can be started with 10 units, and its dose can be 
gradually increased by 2 units if fasting BGLs have 
not achieved the target [16]. Other literature declare 
that the initial daily dose of insulin can be started with 
0.5-1.5 unit per kilogram body weight, then the insulin 
dose can be divided into basal insulin dose (50% of 
the initial daily dose) and prandial insulin dose (50% 
of the initial daily dose). Following the physiological 
condition of the body, insulin therapy is given once for 
basal and three times with prandial insulin for after-
meal [24], [25], [26]. This problem also required the 
attention of health care providers to be able to 
increase the dose of insulin gradually when BGLs 
have not achieved the target of glycemic control. 
The more the complications experienced by 
the patients, the more the number of drugs given to 
the patients and the higher the incidence of drug 
interactions [27]. This was in line with several studies 
which state that polypharmacy is closely related to 
DRP [28]. This was also proven based on the results 
of a study undertaken in Malaysia, which proved that 
there was a significant relationship between 
polypharmacy and drug interactions [20]. Increasing 
the number of prescripted drugs can increase the risk 
of drug interactions, poor control of BGLs and 
therapeutic outcomes. Therefore, routine monitoring 
and resolving of inappropriate clinical outcomes and 
clinically significant drug interactions are needed to 
optimise drug therapy [21]. The most common drugs 
involved in drug interactions were insulin with 
angiotensin receptor blocker, aspirin, quinolone and 
ace inhibitor. It was dissimilar to the study that 
reported aspirin, clopidogrel, simvastatin, amlodipine, 
beta-blockers, NSAIDs agents and ACE inhibitors 
were most implicated in drug interactions [20], [29]. 
The differences can be caused by the difference in 
complications experienced by these patients, so the 
prescribed drugs will be different. The drug 
interactions were identified in this study with major 
and moderate clinical significance levels, which can 
affect changes in BGLs based on ensured literature 
and evidence. Clinicians can still use the drug 
simultaneously with close monitoring of BGLs and 
followed by the appropriate actions [20].  
In this study, hypoglycemia experienced by 10 
T2DM patients is an undesirable drug therapy 
outcome due to drug interactions, and side effects 
resulted in the provision of insulin or oral antidiabetic 
drug. This was consistent with many studies reported 
incidences hypoglycemia related to the use of insulin 
and sulfonylurea [30], [31]. Hypoglycemia can occur at 
any time. Therefore, routine monitoring of BGLs and 
appropriate efforts are needed to avoid recurrence of 
hypoglycemia.  
It can be concluded that DRPs has a 
significant effect on BGLs in the treatment of patients 
with T2DM. DRPs of dose selection affects the BGL of 
hyperglycemia and DRPs of drug interactions, and 
unwanted drug reactions affect the occurrence of 
hypoglycemia. With the proven influence of DRPs on 
changes in BGLs in the treatment of T2DM patients, 
the active role of pharmacists as a part of the 
healthcare providers is crucial to identify and resolve 
the presence of DRPs which in turns optimise the 
treatment of patients with T2DM. 
 
 
References 
 
1. Cho N, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes 
JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global 
estimates of diabetes prevalence for 2017 and projections for 
2045. Diabetes research and clinical practice. 2018; 138:271-81. 
https://doi.org/10.1016/j.diabres.2018.02.023 PMid:29496507  
2. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, 
Hirst M, Hwang C, Magliano D, Patterson C, Scott C. IDF diabetes 
atlas, 2010. 
 
3. Standards of Medical Care for Patients With Diabetes Mellitus. 
Diabetes Care. American Diabetes Association; 1996; 
19(Supplement 1):S8-S15. https://doi.org/10.2337/diacare.19.1.S8 
 
4. Jamal I, Amin F, Jamal A, Saeed A. Pharmacist's interventions 
in reducing the incidences of drug related problems in any practice 
setting. International current pharmaceutical journal. 2015; 
4(2):347-52. https://doi.org/10.3329/icpj.v4i2.21483 
 
5. Pharmaceutical Care Network Europe Foundation: PCNE 
classification for drug-related problems, V8.02. 2017.  
6. Yosephine L. Systemic challenges impede Indonesia's universal 
health care ambitions. Assessed on 22th October 2017.  
7. Rachman A. Indonesia's Health-Care Program Struggles with Its 
Own Success. The Walls Street Journal. 2015.  
8. Siti P, Ahmad AZ, Husni M. Analysis of drug related problems of 
renal failure patients with diabetes mellitus complications in  
Hartuti et al. The Effect of Drug Related Problems on Blood Glucose Level in the Treatment of Patients with Type 2 Diabetes Mellitus 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         5 
 
regional hospital. PharmaXplore, 2018. 
9. Azizah N, Khairunnisa, Hari RT. Drug Therapy Problems In 
Management of Hypertensive Outpatients Admitted To Four 
Indonesian Primary Health Centers. Asian J Pharm Clin Res. 2016; 
87-90. 
 
10. Law AM, Kelton WD, Strand LM, Morley PC. Pharmaceutical 
Care Practice: The Clinicians Guide. McGraw-Hill, 2004.  
11. Tatro DS, Wickersham RM. Drug interaction facts: the authority 
on drug interactions, 2009. Missouri: Wolters Kluwer Health, 2009.  
12. Stockley IH. Drug Interaction: A Source Book of Adverse 
Interactions, Their Mechanisms, Clinical Importance and 
Management. 5th ed. London: Pharmaceutical Press, 2001. 
 
13. Medscape Reference. Assessed online October 1st to 
November 17 th. 
http://www.emedicine.medscape.com/article/241381-medication. 
 
14. IBM Micromedex Reference. Assessed online August 28 th to 
November 27 th. Available from 
http://www.micromedexsolutions.com/micromedex2/librarian. 
 
15. World Health Organization. Global Report on diabetes. 
Geneva: World Health Organization, 2017.  
16. American Diabetes Association. Standards of Medical Care In 
Diabetes. 2017; 40(Suppl.1): S11-S64. 
https://doi.org/10.2337/dc17-S005 PMid:27979889  
 
17. Home P, Mant J, Diaz J, Turner C. Management of type 2 
diabetes: summary of updated NICE guidance. Bmj. 2008; 
336(7656):1306-8. https://doi.org/10.1136/bmj.39560.442095.AD 
PMid:18535074 PMCid:PMC2413390 
 
18. American Association of Clinical Endocrinologists and 
American College of Endocrinology - Clinical Practice Guidelines 
for Developing a Diabetes Mellitus Comperehensive Care Plan - 
2015. Endocrinbe Practice. 2015; 21 (sppl1):1-87 
 
19. Janes J. Categorical relationships: chi-square. Library Hi Tech. 
2001; 19(3):296-8. https://doi.org/10.1108/EUM0000000005892  
20. Huri HZ, Wee HF. Drug related problems in type 2 diabetes 
patients with hypertension: a cross-sectional retrospective study. 
BMC endocrine disorders. 2013; 13(1):2. 
https://doi.org/10.1186/1472-6823-13-2 PMid:23289895 
PMCid:PMC3542270 
 
21. Ogbonna BO, Ezenduka CC, Opara CA, Ahara L. Drug therapy 
problems in patients with Type-2 Diabetes in a tertiary hospital in 
Nigeria. Int J Innov Res Dev. 2014; 3(1):494-502. 
 
22. Shareef JA, Fernandes J, Samaga L, Khader SA. A study on 
 
adverse drug reactions in hospitalized patients with diabetes 
mellitus in a multi-speciality teaching hospital. Asian Journal of 
Pharmaceutical Clinical Research. 2016; 9(2):114-7. 
23. Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes 
prevalence and socioeconomic status: a population based study 
showing increased prevalence of type 2 diabetes mellitus in 
deprived areas. Journal of Epidemiology & Community Health. 
2000; 54(3):173-7. https://doi.org/10.1136/jech.54.3.173 
PMid:10746110 PMCid:PMC1731634 
 
24. Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ. 
Applied Therapeutics: The Clinical Use of Drugs, 8th ed, Lippincott 
Williams and Wilkin, Philadelphia, 2005. 
 
25. Cheng AYY, Zinman B, Khan CR, et al. (Eds). Joslin's Diabetes 
Mellitus. Fourth Edition. Lipincott Williams & Wilkins. Philadelphia, 
2005. 
 
26. Bode BW, Braithwaite SS, Steed RD, Davidson PC. 
Intravenous Insulin Infusion Therapy: Indications, Methods, and 
Transition to Subcutaneous Insulin Therapy. Endocrine Practice. 
AACE Corp (American Association of Clinical Endocrinologists); 
2004; 10(Supplement 2):71-80. 
https://doi.org/10.4158/EP.10.S2.71 PMid:15251644  
 
27. Peterson JF, Bates DW. Preventable medication errors: 
identifying and eliminating serious drug interactions. Journal of the 
American Pharmaceutical Association. 2001; 41(2):159-60. 
https://doi.org/10.1016/S1086-5802(16)31243-8 
 
28. Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as 
commonly defined is an indicator of limited value in the 
assessment of drug‐related problems. British journal of clinical 
pharmacology. 2007; 63(2):187-95. https://doi.org/10.1111/j.1365-
2125.2006.02744.x PMid:16939529 PMCid:PMC2000563 
 
29. Koh Y, Kutty FB, Li SC. Drug-related problems in hospitalized 
patients on polypharmacy: the influence of age and gender. 
Therapeutics and clinical risk management. 2005; 1(1):39-48. 
https://doi.org/10.2147/tcrm.1.1.39.53597 PMid:18360542 
PMCid:PMC1661606 
 
30. Pizzimenti V, Ientile V, Fava G, Giudice I, Bonfiglio C, Alecci U, 
et al. Adverse reactions with anti-diabetic drugs: Results from a 
prospective cohort study in Sicily, 2015. 
 
31. Alex SM, Sreelekshmi BS, Smitha S, Jiji KN, Menon AS, Uma 
Devi P. Drug utilization pattern of anti-diabetic drugs among 
diabetic outpatients in a tertiary care hospital. Asian Journal of 
Pharmaceutical and Clinical Research. 2015; 8(2). 
 
 
